Publication | Open Access

Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial

Neuro-oncologyPrognostic BiomarkersBiomarker AnalysisBrain MetastasesMedicineCancer ManagementClinical TrialsImmune Checkpoint InhibitorPharmacotherapyCancer TreatmentOncologyRadiation OncologyLong-term ResultsHealth Sciences